PCSA
Processa Pharmaceuticals Inc

4,679
Mkt Cap
$5.96M
Volume
18,618.00
52W High
$19.63
52W Low
$1.76
PE Ratio
-0.13
PCSA Fundamentals
Price
$2.24
Prev Close
$2.30
Open
$2.29
50D MA
$2.65
Beta
0.94
Avg. Volume
49,391.12
EPS (Annual)
-$10.36
P/B
1.03
Rev/Employee
$0.00
$1.77
Loading...
Loading...
Poll

Earnings Recap

Processa Pharmaceuticals Inc. reported a net loss of $13.6M for the year ended December 31, 2025, with $11.4M in net cash used in operating activities and $5.5M in cash and cash equivalents.

Bullish

Processa Pharmaceuticals Inc. is advancing NGC-Cap in Phase 2 with high potency and PCS12852 in Phase 2A with positive results, leveraging its Regulatory Science Approach to reduce clinical and regulatory risks.

Bearish

Processa Pharmaceuticals Inc. faces substantial doubt about its ability to continue operations due to recurring losses and significant cash burn, compounded by reliance on third-party manufacturers and digital asset volatility.

Latest PCSA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.